Overview
NICE is unable to make a recommendation on NBTXR-3 for treating advanced soft tissue sarcoma. This is because Nanobiotix did not provide an evidence submission.
Last reviewed: 10 November 2021
Next review: We will review this decision if the company decides to make a submission.